Vilanterol: all 73 studies that test it

Page 1 of 1. Open to participants first (5), then studies with results posted, then the rest; newest registration first within each.

• 129-Xe MRI Study of Single Triple Therapy Inhaler Effects in COPD Patients With Moderate-severe Dyspnea and/or Poor Health Status With High or Low Risk of ExacerbationRecruitingNCT07192016Phase 4
• Effect of the Inhaled Triple Therapies Over the Small Airway in Biomass ExposureRecruitingNCT06571942Phase 4
• Role of Lung Function for Exercise Capacity in Well-trained IndividualsRecruitingNCT06077019Not applicable
• U-LABA/ICS Effects on Exercise Performance, VilanterolRecruitingNCT06066606Not applicable
• A Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With AsthmaRecruitingNCT05757102Phase 3
• To Evaluate Real-World Effectiveness of Fluticasone Furoate/Umeclidinium Bromide/Vilanterol (FF/UMEC/VI) in a Single Inhaler (Trelegy Ellipta) in Participants With Symptomatic COPDCompletedNCT05535972Phase 4Results posted
• Efficacy and Safety of Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) in Chinese Participants With Inadequately Controlled AsthmaCompletedNCT04937387Phase 3Results posted
• A Study to Evaluate the Safety and Efficacy of Fluticasone Furoate (FF)/Umeclidinium(UMEC)/Vilanterol (VI) in Participants With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT04923347Phase 4Results posted
• Evaluation of Triple Therapy Using Magnetic Resonance Imaging in AsthmaActive, not recruitingNCT04651777Phase 3Results posted
• A Randomized Study, Comparing Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC /VI) Single Inhaler Triple Therapy, Versus Multiple Inhaler Therapy (Budesonide/Formoterol Plus Tiotropium) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT03478696Phase 4Results posted
• A Randomized Study, Comparing Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Single Inhaler Triple Therapy, Versus Multiple Inhaler Therapy (Budesonide/Formoterol Plus Tiotropium) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT03478683Phase 4Results posted
• A Comparative Study Between Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Single Inhaler Triple Therapy Versus Tiotropium Monotherapy in Subjects With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT03474081Phase 4Results posted
• INTREPID: Investigation of TRELEGY Effectiveness: Usual Practice DesignCompletedNCT03467425Phase 4Results posted
• Comparative Study of Fluticasone Furoate(FF)/Umeclidinium Bromide (UMEC)/ Vilanterol (VI) Closed Therapy Versus FF/VI Plus UMEC Open Therapy in Subjects With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT02729051Phase 3Results posted
• A Phase IIA FF/VI Study to Measure FeNO in Asthmatic Patients.CompletedNCT02712047Phase 2Results posted
• Dose-Finding Study of Batefenterol (GSK961081) Via Dry Powder Inhaler in Patients With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT02570165Phase 2Results posted
• Efficacy and Safety Study of Indacaterol Maleate/Glycopyrronium Bromide in Chronic Obstructive Pulmonary Disease (COPD) Patients.CompletedNCT02487498Phase 3Results posted
• Efficacy and Safety Study of QVA149 in COPD PatientsCompletedNCT02487446Phase 3Results posted
• A Study to Compare the Efficacy of Fluticasone Furoate/Vilanterol Inhalation Powder With Usual Inhaled Corticosteroids (ICS)/Long Acting Beta Agonists (LABA) in Persistent AsthmaCompletedNCT02446418Phase 3Results posted
• Study Evaluating the Efficacy and Safety of Fluticasone Furoate/Vilanterol Inhalation Powder (FF/VI) Compared With Vilanterol Inhalation Powder (VI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT02105974Phase 3Results posted
• A Study to Compare the Efficacy and Safety of Fluticasone Furoate (FF) 100 mcg Once Daily With Fluticasone Propionate (FP) 250 mcg Twice Daily (BD) and FP 100 mcg BD in Well-controlled Asthmatic Japanese SubjectsCompletedNCT02094937Phase 3Results posted
• Study Evaluating the Effect of Fluticasone Furoate/ Vilanterol (FF/VI) Inhalation Powder Compared With Vilanterol (VI) Inhalation Powder on Bone Mineral Density (BMD) in Subjects With Chronic Obstructive Pulmonary Disease (COPD).CompletedNCT01957150Phase 4Results posted
• A Study to Evaluate the Efficacy and Safety of Umeclidinium Bromide/Vilanterol Compared With Fluticasone Propionate/Salmeterol Over 12 Weeks in Subjects With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT01822899Phase 3Results posted
• A Study to Compare the Efficacy and Safety of Umeclidinium/Vilanterol and Fluticasone Propionate/Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT01817764Phase 3Results posted
• An Effectiveness Study Comparing Fluticasone Furoate (FF, GW685698)/Vilanterol (VI, GW642444) With Standard Treatment in AsthmaCompletedNCT01706198Phase 3Results posted
• RELOVAIR® Lung Deflation StudyCompletedNCT01691885Phase 3Results posted
• Dose-ranging Study of Vilanterol (VI) Inhalation Powder in ChildrenCompletedNCT01573767Phase 2Results posted
• A Randomised Effectiveness Study Comparing Fluticasone Furoate (FF, GW685698)/Vilanterol (VI, GW642444) With Standard Treatment in Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT01551758Phase 3Results posted
• Pharmacokinetics and Pharacodynamics of GW642444 in Paedetric SubjectsCompletedNCT01453296Phase 2Results posted
• Inhaled Fluticasone Furoate/Vilanterol Safety and Tolerability, PK and PD StudyCompletedNCT01453023Phase 2Results posted
• A 24-week Study of Fluticasone Furoate/Vilanterol Inhalation Powder in Subjects of Asian Ancestry With COPDCompletedNCT01376245Phase 3Results posted
• A 24-week Arterial Stiffness Study With Fluticasone Furoate/Vilanterol in COPDCompletedNCT01336608Phase 3Results posted
• An Exercise Endurance Study to Evaluate the Effects of Treatment of Chronic Obstructive Pulmonary Disease (COPD) Patients With a Dual Bronchodilator: GSK573719/GW642444. Study ACompletedNCT01328444Phase 3Results posted
• An Exercise Endurance Study to Evaluate the Effects of Treatment of Chronic Obstructive Pulmonary Disease (COPD) Patients With a Dual Bronchodilator: GSK573719/GW642444.Study BCompletedNCT01323660Phase 3Results posted
• 24-week Trial Comparing GSK573719/GW642444 With GW642444 and With Tiotropium in Chronic Obstructive Pulmonary DiseaseCompletedNCT01316900Phase 3Results posted
• Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol on Survival in Subjects With Chronic Obstructive Pulmonary DiseaseCompletedNCT01313676Phase 3Results posted
• A 24-week Evaluation of GSK573719/Vilanterol (125/25mcg) and Components in COPDCompletedNCT01313637Phase 3Results posted
• Study B2C112060: A Study of the Efficacy and Safety of Vilanterol Inhalation Powder in Adults and Adolescents With Persistent AsthmaCompletedNCT01181895Phase 3Results posted
• Randomised Study Comparing the Effects of Inhaled Fluticasone Furoate (FF)/Vilanterol (VI; GW642444M) Combination and FF on an Allergen Induced Asthmatic ResponseCompletedNCT01128569Phase 2Results posted
• Asthma Exacerbation StudyCompletedNCT01086384Phase 3Results posted
• Efficacy and Safety Study of Fluticasone Furoate (FF)/GW642444 Inhalation Powder and the Individual Components in Subjects With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT01054885Phase 3Results posted
• A 6-month Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT01053988Phase 3Results posted
• Fluticasone Furoate/GW642444 Inhalation Powder Long-Term Safety StudyCompletedNCT01018186Phase 3Results posted
• A Study to Evaluate Annual Rate of Exacerbations and Safety of 3 Dosage Strengths of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT01017952Phase 3Results posted
• A Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT01009463Phase 3Results posted
• Safety and Tolerability of Repeat Dosing of GSK233705/GW642444 in COPDCompletedNCT00749411Phase 2Results posted
• A Study To Assess Efficacy And Safety Of Different Doses Of GW642444 In Subjects With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT00606684Phase 2Results posted
• A Study To Assess The Safety And Tolerability Of GW642444 In Subjects With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT00372112Phase 2Results posted
• Comparative Efficacy of Once-daily LAMA/LABA Combinations Versus Tiotropium on Constant-work-rate Cycle Endurance in COPDSuspendedNCT07541378Not applicable
• Comparative Effects of Triple Inhaled Therapy With Budesonide/Glycopyrronium/Formoterol Versus Fluticasone Furoate/Umeclidinium/Vilanterol on Small Airway Disease in COPD Patients: A Randomized Crossover StudyCompletedNCT06905483Phase 4
• Effect of Fluticasone Furoate/Vilanterol on EIA in AdolescentsCompletedNCT04750603Phase 4
• Effect of Perioperative Bronchodilator in COPD Patients Undergoing Lung Cancer SurgeryActive, not recruitingNCT04536675Phase 3
• Effect of Dual Bronchodilation With Umeclidinium/Vilanterol on Patients With COPD, Hyperinflation and Heart FailureCompletedNCT04522596Phase 4
• Legend: TRELEGY Real World Chronic Obstructive Pulmonary Disease (COPD) Effectiveness StudyWithdrawnNCT03949842Phase 4
• Effectiveness of Fluticasone Furoate/ Umeclidinium/ Vilanterol (FF/UMEC/VI) Using the Connected Inhaler System (CIS) as Compared With Fluticasone Proprionate/ Salmeterol (FP/SAL) Plus Tiotropium (TIO) in Inadequately Controlled AsthmaWithdrawnNCT03376932Phase 3
• The Efficacy of Fluticasone Furoate/Vilanterol Versus (vs) Fluticasone Furoate on AsthmaWithdrawnNCT03363191Phase 4
• Effect of Vilanterol on Methacholine Challenge ResultsCompletedNCT03315000Phase 4
• INvestigating COPD Outcomes, Genomics and Neutrophilic Inflammation With Tiotropium and OlodaterolCompletedNCT03152149Phase 4
• Relovair PD PK in Chinese Healthy SubjectsCompletedNCT01711463Phase 1
• A Study to Assess the Effects of GSK573719/VI Combination and GSK573719 Monotherapy in Subjects With Moderate Hepatic Impairment and Matched Healthy VolunteersCompletedNCT01577680Phase 1
• Study to Assess the Safety and PK of GSK573719 and GSK573719/GW642444(VI) Combination in Healthy Subjects and Subjects With Severe Renal ImpairmentCompletedNCT01571999Phase 1
• Bioequivalence Study to Compare Fluticasone Furoate (FF) 1-strip Inhaler With FF 2-strip Inhaler and With FF/Vilanterol CombinationCompletedNCT01485445Phase 1
• Study to Look at and Compare How Inhaled and Intravenous Fluticasone Furoate and GW642444 Are Processed by the Body in Healthy SubjectsCompletedNCT01299558Phase 1
• A Single Dose Study to Determine the Excretion, Balance and Metabolic Disposition of Radiolabelled GW642444.CompletedNCT01286831Phase 1
• Dose Proportionality Study: Blood Levels of Fluticasone Furoate (FF) and Vilanterol (VI) Following Different Doses of FF/VI Via an InhalerCompletedNCT01213849Phase 1
• Phase I Study of GW642444M in Healthy Japanese Male SubjectsCompletedNCT00964249Phase 1
• A Study to Assess the Safety and Pharmacokinetics of Inhaled Doses of GSK233705 and GW642444 in Healthy SubjectsCompletedNCT00783003Phase 1
• A Study To Investigate Safety, Blood Levels And Effects Of Giving GW642444, By Mouth, By Inhalation & By InjectionCompletedNCT00711126Phase 1
• A Study to Investigate the Effect of Inhaling Single Doses of Different Formulations of GW642444M in Asthmatic PatientsCompletedNCT00702910Phase 1
• A Study to Assess the Safety and Pharmacokinetics of Inhaled Doses of GSK233705 and GW642444 in Healthy Subjects.CompletedNCT00671216Phase 1
• Comparing Two Respiratory Drugs in Combination and Separately From a Novel Inhaler Device in Healthy Japanese SubjectsCompletedNCT00625196Phase 1
• Investigation Of A New Medication (GW642444) In Asthmatic PatientsCompletedNCT00354874Phase 2
• Repeat Doses Of A New Medication (GW642444) In Asthmatic PatientsCompletedNCT00347139Phase 2

← Vilanterol overview